EUVIMEDEUVIMED entdecken
Crossref

Targeting mevalonate pathway by zoledronate ameliorated pulmonary fibrosis in a rat model: Promising therapy against post‐COVID‐19 pulmonary fibrosis

Reham Hussein Mohamed iD, Nesma Hussein Abdel Hay, Nesma Mohamed Fawzy, Yomna M Tamim, M M Doaa Karem, Dalia Ahmed Yousef Yehia, Omnia M Abdel Maksoud, Dina S Abdelrahim

Fundamental & Clinical Pharmacology · 2024

DOI: 10.1111/fcp.12994 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2024. Verfasst von Reham Hussein Mohamed und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Rats, Wistar, Pulmonary Fibrosis, rho-Associated Kinases, Zoledronic Acid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rho kinase (ROCK) pathway plays a critical role in post‐COVID‐19 pulmonary fibrosis (PCPF) and its intervention with angiotensin‐converting enzyme 2 (ACE2) and vascular endothelial growth factor (VEGF) will be a potential therapeutic target.

Objectives

The present study was conducted to investigate the efficacy of zoledronate (ZA) on carbon tetrachloride (CCl4) induced pulmonary fibrosis (PF) in rats through targeting ACE2, ROCK, and VEGF signaling pathways.

Methods

Fifty male Wistar rats were divided into five groups: control, vehicle‐treated, PF, PF‐ZA 50, and PF‐ZA 100 groups. ZA was given in two different doses 100 and 50 μg/kg/week intraperitoneally. After anesthesia, mean arterial blood pressure (MBP) was measured. After scarification, lung coefficient was calculated. Lung levels of ACE 2, interleukin‐1β (IL‐1β), transforming growth factor‐β (TGF‐β), VEGF, glutathione (GSH), and superoxide dismutase (SOD) were measured. Expression of ROCK, phosphorylated myosin phosphatase target subunit 1 (P‐MYPT1), and matrix metalloproteinase (MMP‐1), along with histopathological changes and immune‐histochemical staining for lung α‐smooth muscle actin (α‐SMA), tumor necrosis factor‐alpha (TNFα), and caspase‐3, were evaluated.

Results

ZA significantly prevented the decrease in MBP. ZA significantly increased ACE2, GSH, and SOD and significantly decreased IL‐1β, TGF‐β, and VEGF in lung in comparison to PF group. ZA prevented the histopathological changes induced by CCl4. ZA inhibited lung expression of ROCK, P‐MYPT1, MMP‐1, α‐SMA, TNFα, and caspase‐3 with significant differences favoring the high dose intervention.

Conclusion

ZA in a dose‐dependent manner prevented the pathological effect of CCl4 in the lung by targeting mevalonate pathway. It could be promising therapy against PCPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rats, WistarPulmonary Fibrosisrho-Associated KinasesZoledronic AcidDisease Models, AnimalMevalonic AcidAnimalsMaleRatsVascular Endothelial Growth Factor ACOVID-19Signal TransductionCOVID-19 Drug TreatmentLungAngiotensin-Converting Enzyme 2

Stichwörter der Autor:innen

ACE2COVID‐19ROCKVEGFpulmonary fibrosiszoledronate

Substanzen

rho-Associated KinasesZoledronic AcidMevalonic AcidVascular Endothelial Growth Factor AAngiotensin-Converting Enzyme 2

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Department of Histology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Department of Medical Physiology, Faculty of Medicine, Cairo University, Cairo, Egypt.
  • Department of Pharmacology, Faculty of Medicine, Modern Technology and Information University, Cairo, Egypt.

ORCID-Profile: Reham Hussein Mohamed

Zitieren

APA

Mohamed, R. H., Abdel Hay, N. H., Fawzy, N. M., Tamim, Y. M., Doaa Karem, M. M., Yehia, D. A. Y., Abdel Maksoud, O. M., & Abdelrahim, D. S. (2024). Targeting mevalonate pathway by zoledronate ameliorated pulmonary fibrosis in a rat model: Promising therapy against post‐COVID‐19 pulmonary fibrosis. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12994

Vancouver

Mohamed RH, Abdel Hay NH, Fawzy NM, Tamim YM, Doaa Karem MM, Yehia DAY, et al. Targeting mevalonate pathway by zoledronate ameliorated pulmonary fibrosis in a rat model: Promising therapy against post‐COVID‐19 pulmonary fibrosis. Fundamental & Clinical Pharmacology. 2024. doi:10.1111/fcp.12994

BibTeX
@article{Mohamed2024,
  author = {Mohamed, Reham Hussein and Abdel Hay, Nesma Hussein and Fawzy, Nesma Mohamed and Tamim, Yomna M and Doaa Karem, M M and Yehia, Dalia Ahmed Yousef and Abdel Maksoud, Omnia M and Abdelrahim, Dina S},
  title = {Targeting mevalonate pathway by zoledronate ameliorated pulmonary fibrosis in a rat model: Promising therapy against post‐COVID‐19 pulmonary fibrosis},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/fcp.12994}
}
Kostenlos starten →